Meet Prostate Cancer Surgeon Peter Scardino
Peter T. Scardino, MD, FACS
David H. Koch Chair
Urologic Oncology; Prostate Cancer
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Scardino accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, Duke University School of Medicine
Surgery - Massachusetts General Hospital; Urology - University of California Los Angeles
National Cancer Institute
As Chairman of the Department of Surgery for more than ten years, I oversaw a department widely recognized for its expertise and innovation in cancer surgery. In addition to my administrative responsibilities, I am a surgeon specializing in prostate cancer. My expertise is in early detection, prognosis, and surgical treatment of prostate cancer. Radical prostatectomy — complete removal of the prostate — can cure many men with prostate cancer. Our team has developed surgical techniques to preserve urinary and sexual function after prostatectomy, and we continue to seek ways to improve quality of life for patients after treatment.
Not all prostate cancers progress in the same way. Many cancers pose little or no threat to life and health, while others grow aggressively and are resistant to treatment. My colleagues and I have pioneered the use of statistical models to predict both the natural progression of prostate cancer and how it will respond to treatment. These predictive tools (nomograms) help us tailor treatment for individual men according to the specific characteristics of their cancer. Today, nomograms are being used to help physicians and patients make medical decisions regarding a variety of other cancers as well, including pancreatic, lung, and breast cancer.
In 2001, I received an NIH grant to establish an ongoing Specialized Program of Research Excellence (SPORE) in prostate cancer at Memorial Sloan Kettering Cancer Center. Our SPORE has an ambitious research program focused on developing therapies appropriate for patients with different types of prostate cancer at different stages of development. We hope to achieve this by using molecular and genetic data to improve our prediction models for prostate cancer, identifying the critical mechanisms by which prostate cancer grows and spreads, and developing drugs and immunological techniques for treatment-resistant metastatic cancers.
My position at Memorial Sloan Kettering includes appointments as Head of the Prostate Cancer program, Member in the Sloan Kettering Institute’s Molecular Pharmacology Program; and the incumbent of the David H. Koch Chair. I am also a Professor in the Department of Urology at Weill Cornell Medical College and at SUNY Downstate Medical Center.
I have written many articles and book chapters and edited the Comprehensive Textbook of Genitourinary Oncology. In 2005, with Judith Kelman, I wrote Dr. Peter Scardino’s Prostate Book, a guide to prostate cancer, prostatitis, and benign prostate hyperplasia (BPH). I serve as Editor-in Chief of Nature Clinical Practice Urology, and I am an editorial board member and reviewer for several peer-reviewed journals. I am an active member of the National Academies’ Institute of Medicine and of the American Urological Association.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Selected Books and Book Chapters
Peter Scardino’s Prostate Book: The Complete Guide to Overcoming Prostate Cancer, Prostatitis, and BPH. 2nd ed. Scardino PT, Kelman J. New York: Penguin Group; 2010.
Comprehensive Textbook of Genitourinary Oncology. 4th ed. Scardino PT, Linehan MW, Zelefsky MJ, Vogelzang NJ, eds. Philadelphia: Lippincott Williams & Wilkins; 2011.
Interventional Techniques in Uro-oncology. Ahmed HU, Arya M, Scardino PT, Emberton M, eds. London: Blackwell Publishing; 2011.
Contemporary Issues in Cancer Imaging: Prostate Cancer. Hricak H, Scardino PT, eds. Cambridge, UK: Cambridge Univ Press; 2009.
“Anatomical radical prostatectomy in the management of localized prostate cancer.” Lin DW, Eastham JA, Scardino PT. In: Management of Prostate Cancer: Advances and Controversies. Cummings KB, ed. New York: Marcel Dekker, Inc. 2005; 55-60.
“The decision-making process for prostate cancer.” Trabulsi EJ, Scardino PT, Kattan MW. In: Prostate Cancer: Science and Clinical Practice. Mydlo JH and Godec CJ, eds. San Diego: Academic Press; 2004: 232-252.
“Carcinoma of the prostate: Radical prostatectomy.” Scardino PT, Eastham JA. In: Campbell’s Urology. 8th ed. Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, eds. Philadelphia: W.B. Saunders; 2002.
Visit PubMed for a full listing of Dr. Scardino’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Peter T. Scardino discloses the following relationships and financial interests:
OPKO Health, Inc.
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services (uncompensated)
Provision of Services (uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.